Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

Published:2006-07 Issue:1 Volume:43 Page:16-24
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:CLIN INFECT DIS

Author:

Martin Stanley I.,Marty Francisco M.,Fiumara Karen,Treon Steven P.,Gribben John G.,Baden Lindsey R.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/43/1/16/876132/43-1-16.pdf

Reference28 articles.

1. 1.9 Å structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen

2. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

3. Phase II study of alemtuzumab in chronic lymphoproliferative disorders

4. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

5. CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Letermovir for CMV Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant.;Transplantation and Cellular Therapy;2024-09

2. Clinical Mycology Today: Emerging Challenges and Opportunities;Open Forum Infectious Diseases;2024-06-27

3. Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy;Cancer Immunology Research;2024-06-03

4. Using a commercially available assay that measures cytomegalovirus (CMV)-specific T-cell immunity to predict protection against CMV: A prospective, blinded clinical study;Diagnostic Microbiology and Infectious Disease;2024-02

5. Commercial and regulatory challenges in cancer nanomedicine;Functionalized Nanomaterials for Cancer Research;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3